Europe - Frankfurt Stock Exchange - FRA:56S1 - FR0013154002 - Common Stock
The current stock price of 56S1.DE is 220.9 EUR. In the past month the price increased by 10.06%. In the past year, price increased by 19.99%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| DIM.PA | SARTORIUS STEDIM BIOTECH | 49.72 | 20.86B | ||
| SRT3.DE | SARTORIUS AG-VORZUG | 56.43 | 19.27B | ||
| SRT.DE | SARTORIUS AG | 43.51 | 14.86B | ||
| QIA.DE | QIAGEN N.V. | 20.31 | 8.94B | ||
| 1SXP.DE | SCHOTT PHARMA AG& CO KGAA | 15.87 | 2.32B | ||
| EVT.DE | EVOTEC SE | N/A | 2.24B | ||
| GXI.DE | GERRESHEIMER AG | 7.47 | 952.61M | ||
| FF.MI | FINE FOODS & PHARMACEUTICALS | 10.38 | 203.83M | ||
| ALECR.PA | EUROFINS CEREP-REGR | 24.9 | 178.00M | ||
| MLC.I | MALIN CORP PLC | N/A | 34.64M |
Sartorius Stedim Biotech SA provides equipment and services for the development, quality assurance, and production processes of the biopharmaceutical industry. The company is headquartered in Aubagne, Paca and currently employs 10,134 full-time employees. The firm covers the segments of biotechnology and mechatronics. Sartorius provides services which help customers to implement complex and quality-critical processes in biopharmaceutical production and laboratory environments in a time- and cost-efficient way. The Company’s customers are from the biotech, pharma and food industries, as well as from public research institutes and laboratories. Sartorius operates its own production facilities in Europe, Asia and America, and also has sales offices and local representatives in more than 110 countries. The firm operates through its subsidiaries, including Sartorius Stedim Austria GmbH, Sartorius Stedim Plastics GmbH, BioOutsource Ltd and Wave Biotech AG, among others.
SARTORIUS STEDIM BIOTECH
Zone Industrielle les Paluds Avenue de Jouques, Bp 1051, Aubagne Cedex
Aubagne PACA FR
Employees: 9961
Phone: 33442845600
Sartorius Stedim Biotech SA provides equipment and services for the development, quality assurance, and production processes of the biopharmaceutical industry. The company is headquartered in Aubagne, Paca and currently employs 10,134 full-time employees. The firm covers the segments of biotechnology and mechatronics. Sartorius provides services which help customers to implement complex and quality-critical processes in biopharmaceutical production and laboratory environments in a time- and cost-efficient way. The Company’s customers are from the biotech, pharma and food industries, as well as from public research institutes and laboratories. Sartorius operates its own production facilities in Europe, Asia and America, and also has sales offices and local representatives in more than 110 countries. The firm operates through its subsidiaries, including Sartorius Stedim Austria GmbH, Sartorius Stedim Plastics GmbH, BioOutsource Ltd and Wave Biotech AG, among others.
The current stock price of 56S1.DE is 220.9 EUR. The price decreased by -0.85% in the last trading session.
SARTORIUS STEDIM BIOTECH (56S1.DE) has a dividend yield of 0.33%. The yearly dividend amount is currently 0.71.
56S1.DE has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on 56S1.DE.
The Revenue of SARTORIUS STEDIM BIOTECH (56S1.DE) is expected to grow by 7.45% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
SARTORIUS STEDIM BIOTECH (56S1.DE) will report earnings on 2026-01-26, after the market close.
ChartMill assigns a technical rating of 10 / 10 to 56S1.DE. When comparing the yearly performance of all stocks, 56S1.DE is one of the better performing stocks in the market, outperforming 83.05% of all stocks.
ChartMill assigns a fundamental rating of 5 / 10 to 56S1.DE. 56S1.DE has an average financial health and profitability rating.
Over the last trailing twelve months 56S1.DE reported a non-GAAP Earnings per Share(EPS) of 4.31. The EPS increased by 35.11% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 8.96% | ||
| ROA | 3.35% | ||
| ROE | 6.54% | ||
| Debt/Equity | 0.5 |
18 analysts have analysed 56S1.DE and the average price target is 240.69 EUR. This implies a price increase of 8.96% is expected in the next year compared to the current price of 220.9.
For the next year, analysts expect an EPS growth of 29.39% and a revenue growth 7.45% for 56S1.DE